Clinicopathological characteristics and prognosis of non-small cell lung cancer in Algeria: a single-center retrospective study.
Algeria
Clinicopathologial features
Non–small-cell lung cancer
Prognosis
Journal
BMC cancer
ISSN: 1471-2407
Titre abrégé: BMC Cancer
Pays: England
ID NLM: 100967800
Informations de publication
Date de publication:
02 Aug 2024
02 Aug 2024
Historique:
received:
28
11
2023
accepted:
26
07
2024
medline:
3
8
2024
pubmed:
3
8
2024
entrez:
2
8
2024
Statut:
epublish
Résumé
Lung cancer is the most commonly diagnosed cancer and the leading cause of cancer-related death in men in Algeria. Little is known about the characteristics of lung cancer in Algeria. This study aimed to determine the clinicopathological characteristics and prognosis of non-small cell lung cancer (NSCLC) patients in Algeria. This retrospective study was performed on 269 pathologically confirmed cases of NSCLC at the Benbadis University Hospital of Constantine (2015-2023). Of these, 95 patients were included in the survival analysis. The clinicopathological and outcome data were investigated based on the patients' medical records. This study showed male predominance with sex ratio of 5.7, with a mean age of 61.8 years. Histologically, 67.3% of cases had adenocarcinoma (ADC) and 22.7% squamous cell carcinoma (SCC). ADC and SCC occurred more frequently in female (p = 0.02) and male (p = 0.003) patients, respectively. Smoking was estimated at 82.2% in men. Over 28% were non-smokers, of which 50.7% were women, and presented at younger age (p = 0.04). Most of our patients (75.5%) have an advanced stage at diagnosis. Around 70% of patients underwent chemotherapy (CT) as first-line treatment, with medians diagnostic and treatment delays of 4 and 1 months, respectively. The median overall survival (mOS) was estimated at 10.3 and 6.7 months in I-III and IV stages, respectively. Other factors that negatively impact OS were age > 65 years (p = 0.01), and the presence of symptoms (p = 0.005) and comorbidity (p = 0.004) in stage IV, and delayed treatment (p = 0.03) and receiving CT alone (p = 0.03) in stages I-III cases. Medians progression free survival (mPFS) in stage IV, III, and II patients were 4.1, 5.2, and 8.3 months, respectively, and negatively affected by the comorbidity (stage IV, p = 0.03) and receiving CT alone (stages II-III, p = 0.03). NSCLC presents at an early age and advanced stage in Algerian patients. ADC is the most frequent histological subtype and smoking remains the most important risk factor in men. Furthermore, the prognostic factors affecting survival are stage, age, comorbidity, symptoms, and treatment. Thus, tobacco control, early detection program, and access to novel therapies may be the best strategies to reduce NSCLC morbidity and mortality.
Sections du résumé
BACKGROUND
BACKGROUND
Lung cancer is the most commonly diagnosed cancer and the leading cause of cancer-related death in men in Algeria. Little is known about the characteristics of lung cancer in Algeria. This study aimed to determine the clinicopathological characteristics and prognosis of non-small cell lung cancer (NSCLC) patients in Algeria.
METHODS
METHODS
This retrospective study was performed on 269 pathologically confirmed cases of NSCLC at the Benbadis University Hospital of Constantine (2015-2023). Of these, 95 patients were included in the survival analysis. The clinicopathological and outcome data were investigated based on the patients' medical records.
RESULTS
RESULTS
This study showed male predominance with sex ratio of 5.7, with a mean age of 61.8 years. Histologically, 67.3% of cases had adenocarcinoma (ADC) and 22.7% squamous cell carcinoma (SCC). ADC and SCC occurred more frequently in female (p = 0.02) and male (p = 0.003) patients, respectively. Smoking was estimated at 82.2% in men. Over 28% were non-smokers, of which 50.7% were women, and presented at younger age (p = 0.04). Most of our patients (75.5%) have an advanced stage at diagnosis. Around 70% of patients underwent chemotherapy (CT) as first-line treatment, with medians diagnostic and treatment delays of 4 and 1 months, respectively. The median overall survival (mOS) was estimated at 10.3 and 6.7 months in I-III and IV stages, respectively. Other factors that negatively impact OS were age > 65 years (p = 0.01), and the presence of symptoms (p = 0.005) and comorbidity (p = 0.004) in stage IV, and delayed treatment (p = 0.03) and receiving CT alone (p = 0.03) in stages I-III cases. Medians progression free survival (mPFS) in stage IV, III, and II patients were 4.1, 5.2, and 8.3 months, respectively, and negatively affected by the comorbidity (stage IV, p = 0.03) and receiving CT alone (stages II-III, p = 0.03).
CONCLUSIONS
CONCLUSIONS
NSCLC presents at an early age and advanced stage in Algerian patients. ADC is the most frequent histological subtype and smoking remains the most important risk factor in men. Furthermore, the prognostic factors affecting survival are stage, age, comorbidity, symptoms, and treatment. Thus, tobacco control, early detection program, and access to novel therapies may be the best strategies to reduce NSCLC morbidity and mortality.
Identifiants
pubmed: 39095812
doi: 10.1186/s12885-024-12709-5
pii: 10.1186/s12885-024-12709-5
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
946Informations de copyright
© 2024. The Author(s).
Références
Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries CA. Cancer J Clin. 2021;71(3):209–49. https://doi.org/10.3322/caac.21660
doi: 10.3322/caac.21660
World Health Organization International, Agency for Research on Cancer. GLOBOCAN 2020: estimated cancer incidence, mortality, and prevalence worldwide in 2020. http://globocan.iarc.fr/Pages/fact_sheets_cancer
Cheng T, Cramb TY, Baade SM, Youlden PD, Nwogu DR, Reid C ME. The international epidemiology of lung cancer: latest trends, disparities, and tumor characteristics. J Thorac Oncol. 2016;11(10):1653–71. https://doi.org/10.1016/j.jtho.2016.05.021
doi: 10.1016/j.jtho.2016.05.021
pubmed: 27364315
pmcid: 5512876
Barta JA, Powell CA, Wisnivesky JP. Global epidemiology of lung cancer. Ann Glob Health. 2019;22;85(1):8. https://doi.org/10.5334/aogh.2419
Howlader N, Forjaz G, Mooradian MJ, Meza R, Kong CY, Cronin KA, et al. The effect of advances in lung-cancer treatment on population mortality. N Engl J Med. 2020;13(7):640–9. https://doi.org/10.1056/NEJMoa1916623
doi: 10.1056/NEJMoa1916623
Malhotra J, Malvezzi M, Negri E, La Vecchia C, Boffetta P. Risk factors for lung cancer worldwide. Eur Respir J. 2016;48(3):889–902. https://doi.org/10.1183/13993003.00359-2016
doi: 10.1183/13993003.00359-2016
pubmed: 27174888
Schabath MB, Cote ML. Cancer progress and priorities: lung cancer. Cancer Epidemiol Biomarkers Prev. 2019;28(10):1563–79. https://doi.org/10.1158/1055-9965.EPI-19-0221
doi: 10.1158/1055-9965.EPI-19-0221
pubmed: 31575553
pmcid: 6777859
Harir N, Zeggai S, Maalem A. Epidemiological and pathological profile of lung cancer in West Algeria: about 772 cases. J Afr Cancer. 2015;7:22–6. https://doi.org/10.1007/s12558-014-0336-7
doi: 10.1007/s12558-014-0336-7
Hamdi Cherif M, Kara L, Atoui S, Boudefar F. Données épidémiologiques du cancer dans l’Est et le sud-est Algérien, 2014–2017. Algerian J Health Sci. 2020;2(S2):S14–31.
Bounedjar A, Benkali R, Badoui L, Abada M, Moumeni A, Marouani A, et al. Incidence of lung cancer in males and females in Algeria: the lung cancer registry in Algeria (LuCaReAl). Cancer Epidemiol. 2020;12:69:101799. https://doi.org/10.1016/j.canep.2020.101799
doi: 10.1016/j.canep.2020.101799
Ketfi A, Zanoun N, Laouedj I, Gharnaout M, Fraga S. Cancer bronchique Primitif et risques professionnels dans une population Nord-Africaine [Primary lung cancer and occupational exposure in a north African population]. Pan Afr Med J. 2020;5:37:120. https://doi.org/10.11604/pamj.2020.37.120.21755 . French.
doi: 10.11604/pamj.2020.37.120.21755
Missaoui N, Hmissa S, Landolsi H, Korbi S, Joma W, Anjorin A, et al. Lung cancer in central Tunisia: epidemiology and clinicopathological features. Asian Pac J Cancer Prev. 2011;12(9):2305–9. PMID: 22296375.
pubmed: 22296375
Ben Amar J, Ben Safta B, Zaibi H, Dhahri B, Baccar MA, Azzabi S. Facteurs pronostiques Du cancer Bronchique non à petites cellules localement avancé et métastatique. Tunis Med. 2016;94:5. https://doi.org/10.1016/j.pneumo.2017.05.002
doi: 10.1016/j.pneumo.2017.05.002
Harizi C, Bellali H, Hchaichi A, Hamzaoui A, Chahed K. Estimation Du coût de la prise en charge Du cancer broncho-pulmonaire en tunisie. East Mediterr Health J. 2018;24(10):988–93. https://doi.org/10.26719/2018.24.10.988
doi: 10.26719/2018.24.10.988
pubmed: 30582141
Belmokhtar KY, Tajir M, Boulouiz R, Bennani A, Brahmi SA, Alloubi I, et al. Cancer Du Poumon Au Maroc Oriental: où en sommes-nous? [Lung cancer in Eastern Morocco: where do we stand?]. Pan Afr Med J. 2019;34:177. https://doi.org/10.11604/pamj.2019.34.177.19934
doi: 10.11604/pamj.2019.34.177.19934
pubmed: 32153717
pmcid: 7046119
Lachgar A, Tazi MA, Afif M, Er-Raki A, Kebdani T, Benjaafar N. Lung cancer: incidence and survival in Rabat, Morocco. Rev Epidemiol Sante Publique. 2016;64(6):391–5. https://doi.org/10.1016/j.respe.2016.02.012
doi: 10.1016/j.respe.2016.02.012
pubmed: 27793413
Oukabli M, Rharrassi I, Damiri A, et al. Cancers bronchopulmonaires: étude Clinique et anatomopathologique. À propos de 163 cas. J Afr Cancer. 2011;3:29–35. https://doi.org/10.1007/s12558-010-0130-4
doi: 10.1007/s12558-010-0130-4
Jazieh AR, Algwaiz G, Errihani H, Elghissassi I, Mula-Hussain L, Bawazir AA, Gaafar R. Lung cancer in the Middle East and north Africa region. J Thorac Oncol. 2019;14(11):1884–91. https://doi.org/10.1016/j.jtho.2019.02.016
doi: 10.1016/j.jtho.2019.02.016
pubmed: 31668315
Tazi MA, Er-Raki A, Benjaafar N. Cancer incidence in Rabat, Morocco: 2006–2008. Ecancermedicalscience. 2013;8;7:338. https://doi.org/10.3332/ecancer.2013.338
Galvez-Nino M, Ruiz R, Pinto JA, Roque K, Mantilla R, Raez LE, et al. Lung cancer in the young. Lung. 2020;198(1):195–200. https://doi.org/10.1007/s00408-019-00294-5
doi: 10.1007/s00408-019-00294-5
pubmed: 31773258
Ritchie H, Roser M. (2019) Age structure. Published online at OurWorldInData.org. Retrieved from: https://ourworldindata.org/age-structure
Zhang T, Joubert P, Ansari-Pour N, Zhao W, Hoang PH, et al. Genomic and evolutionary classification of lung cancer in never smokers. Nat Genet. 2021;53(9):1348–59. https://doi.org/10.1038/s41588-021-00920-0
doi: 10.1038/s41588-021-00920-0
pubmed: 34493867
pmcid: 8432745
Dias M, Linhas R, Campainha S, Conde S, Barroso A. Lung cancer in never smokers - what are the differences? Acta Oncol. 2017;56(7):931–5. https://doi.org/10.1080/0284186X.2017.1287944
doi: 10.1080/0284186X.2017.1287944
pubmed: 28514931
Shan L, Zhang L, Zhu X, Wang Z, Fang S, Lin J. et al. Chinese never smokers with adenocarcinoma of the lung are younger and have fewer lymph node metastases than smokers. Respir Res. 2022;29;23(1):293. https://doi.org/10.1186/s12931-022-02199-z
Tsoi CT, Tse LA. Professional drivers and lung cancer: a systematic review and meta-analysis. Occup Environ Med. 2012;69(11):831–6. https://doi.org/10.1136/oemed-2012-100666
doi: 10.1136/oemed-2012-100666
pubmed: 22767869
Travis WD, Brambilla E, Nicholson AG, Yatabe Y, Austin JHM, Beasley MB, WHO Panel. The 2015 World Health Organization classification of lung tumors. J Thorac Oncol. 2015;10(9):1243–60. https://doi.org/10.1097/JTO.0000000000000630
doi: 10.1097/JTO.0000000000000630
pubmed: 26291008
Song MA, Benowitz NL, Berman M, Brasky TM, Cummings KM, Hatsukami DK et al. Cigarette filter ventilation and its relationship to increasing rates of lung adenocarcinoma. J Natl Cancer Inst. 2017;1;109(12):djx075. https://doi.org/10.1093/jnci/djx075
Li J, Zhu H, Sun L, Xu W, Wang X. Prognostic value of site-specific metastases in lung cancer: a population-based study. J Cancer. 2019;2;10(14):3079–3086. https://doi.org/10.7150/jca.30463
Athey VL, Walters SJ, Rogers TK. Symptoms at lung cancer diagnosis are associated with major differences in prognosis. Thorax. 2018;73(12):1177–81. https://doi.org/10.1136/thoraxjnl-2018-211596
doi: 10.1136/thoraxjnl-2018-211596
pubmed: 29666219
Xing PY, Zhu YX, Wang L, Hui ZG, Liu SM, Ren JS, LuCCRES Group, et al. What are the clinical symptoms and physical signs for non-small cell lung cancer before diagnosis is made? A nation-wide multicenter 10-year retrospective study in China. Cancer Med. 2019;8(8):4055–69. https://doi.org/10.1002/cam4.2256
doi: 10.1002/cam4.2256
pubmed: 31150167
pmcid: 6639195
Canadian Strategy for Cancer Control. (2001) www.hc-sc.gc.ca/hppb/cscc/work_reports.html
Hanna SJ, Muneer A, Khalil KH. The 2-week wait for suspected cancer: time for a rethink? Int J Clin Pract. 2005;59(11):1334–9. https://doi.org/10.1111/j.1368-5031.2005.00687.x
doi: 10.1111/j.1368-5031.2005.00687.x
pubmed: 16236089
Bourkadi D, Sahraoui K, Zaoui A, Bouchareb A, Bouzidi EE, Bennani MA. Délais De prise en charge Du cancer bronchopulmonaire primitif, expérience Du service de pneumologie B, CHU d’Oran. Rev Mal Respir. 2018;35. Supplement, A221. https://doi.org/10.1016/j.rmr.2017.10.509
Erefai O, Soulaymani A, Mokhtari A, Obtel M, Hami H. Diagnostic delay in lung cancer in Morocco: a 4-year retrospective study. Clin Epidemiol Global Health. 2022;16:101105. https://doi.org/10.1016/j.cegh.2022.101105
doi: 10.1016/j.cegh.2022.101105
PDQ Adult Treatment Editorial Board. Non-small cell lung cancer treatment (PDQ): Health Professional Version. 2023 Feb 17. In: PDQ Cancer Information Summaries. Bethesda (MD): National Cancer Institute (US); 2002. PMID: 26389304.
Kwas H, Guermazi E, Khattab A, Hrizi C, Zendah I, Ghédira H. Facteurs pronostiques du cancer bronchique non à petites cellules Au Stade avancé [Prognostic factors of advanced stage non-small-cell lung cancer]. Rev Pneumol Clin. 2017;73(4):180–7. https://doi.org/10.1016/j.pneumo.2017.05.002 . French.
doi: 10.1016/j.pneumo.2017.05.002
pubmed: 28756002
Islam KM, Jiang X, Anggondowati T, Lin G, Ganti AK. Comorbidity and survival in lung cancer patients. Cancer Epidemiol Biomarkers Prev. 2015;24(7):1079–85. https://doi.org/10.1158/1055-9965
doi: 10.1158/1055-9965
pubmed: 26065838
Polanco D, Pinilla L, Gracia-Lavedan E, Mas A, Bertran S, Fierro G, Seminario A, Gómez S, Barbé F. Prognostic value of symptoms at lung cancer diagnosis: a three-year observational study. J Thorac Dis. 2021;13(3):1485–94. https://doi.org/10.21037/jtd-20-3075
doi: 10.21037/jtd-20-3075
pubmed: 33841941
pmcid: 8024804
Abrao FC, de Abreu IRLB, Rocha RO, Munhoz FD, Rodrigues JHG, Batista BN. Interaction between treatment delivery delay and stage on the mortality from non-small cell lung cancer. J Thorac Dis. 2018;10(5):2813–9. https://doi.org/10.21037/jtd.2018.05.22
doi: 10.21037/jtd.2018.05.22
pubmed: 29997944
pmcid: 6006055
Tsai CH, Kung PT, Kuo WY, Tsai WC. Effect of time interval from diagnosis to treatment for non-small cell lung cancer on survival: a national cohort study in Taiwan. BMJ Open. 2020;22;10(4):e034351. https://doi.org/10.1136/bmjopen-2019-034351
Asmis TR, Ding K, Seymour L, Shepherd FA, Leighl NB, Winton TL, National Cancer Institute of Canada Clinical Trials Group. (2008). Age and comorbidity as independent prognostic factors in the treatment of non small-cell lung cancer: a review of National Cancer Institute of Canada Clinical Trials Group trials. J Clin Oncol. 2008;26(1):54–9. https://doi.org/10.1200/JCO.2007.12.8322
Lembicz M, Gabryel P, Brajer-Luftmann B, Dyszkiewicz W, Batura-Gabryel H. Comorbidities with non-small cell lung cancer: is there an interdisciplinary consensus needed to qualify patients for surgical treatment? Ann Thorac Med. 2018;13(2):101–7. https://doi.org/10.4103/atm.ATM_274_17
doi: 10.4103/atm.ATM_274_17
pubmed: 29675061
pmcid: 5892084
Pezzuto A, Trabalza Marinucci B, Ricci A, Ciccozzi M, Tonini G, D’Ascanio M, Guerrieri G, Chianese M, Castelli S, Rendina EA. Predictors of respiratory failure after thoracic surgery: a retrospective cohort study with comparison between lobar and sub-lobar resection. J Int Med Res. 2022;50(6):3000605221094531. https://doi.org/10.1177/03000605221094531
doi: 10.1177/03000605221094531
pubmed: 35768901
Lee JH, Wu HG, Kim HJ, Kim DW, Lee SH, Kim TM, Kim YW, Heo DS. Influence of comorbidities on the efficacy of radiotherapy with or without chemotherapy in elderly stage III non-small cell lung cancer patients. Cancer Res Treat. 2012;44(4):242–50. https://doi.org/10.4143/crt.2012.44.4.242
doi: 10.4143/crt.2012.44.4.242
pubmed: 23341788
pmcid: 3546271
Blanco JA, Toste IS, Alvarez RF, Cuadrado GR, Gonzalvez AM, Martín IJ. Age, comorbidity, treatment decision and prognosis in lung cancer. Age Ageing. 2008;37(6):715–8. https://doi.org/10.1093/ageing/afn226
doi: 10.1093/ageing/afn226
pubmed: 19004964
Jazieh AR, Onal HC, Tan DSW, Soo RA, Prabhash K, Kumar A, Huggenberger R, Robb S, Cho BC. Real-world treatment patterns and clinical outcomes in patients with stage III NSCLC: results of KINDLE, a multicountry observational study. J Thorac Oncol. 2021;16(10):1733–44. https://doi.org/10.1016/j.jtho.2021.05.003
doi: 10.1016/j.jtho.2021.05.003
pubmed: 34051381
Sakin A, Sahin S, Atci MM, Sakin A, Yasar N, Geredeli C, et al. The effect of different treatment modalities on survival in elderly patients with locally advanced non-small cell lung cancer. Pulmonology. 2021;27(1):26–34. https://doi.org/10.1016/j.pulmoe.2019.11.007
doi: 10.1016/j.pulmoe.2019.11.007
pubmed: 31839507
Flörsch B, Taugner J, Käsmann L, Kenndoff S, Guggenberger J, Tufman A, et al. Treatment patterns and prognosis of patients with inoperable stage III NSCLC after completion of concurrent chemoradiotherapy ± immune checkpoint inhibition: a decade-long single-center historical analysis. J Cancer Res Clin Oncol. 2023;149(7):3267–76. https://doi.org/10.1007/s00432-022-04174-z
doi: 10.1007/s00432-022-04174-z
pubmed: 35915184
Levy MA, Lovly CM, Pao W. Translating genomic information into clinical medicine: lung cancer as a paradigm. Genome Res. 2012;22(11):2101–8. https://doi.org/10.1101/gr.131128.111
doi: 10.1101/gr.131128.111
pubmed: 23019146
pmcid: 3483539
Niu M, Yi M, Li N, et al. Predictive biomarkers of anti-PD-1/PD-L1 therapy in NSCLC. Exp Hematol Oncol. 2021;10:18. https://doi.org/10.1186/s40164-021-00211-8
doi: 10.1186/s40164-021-00211-8
pubmed: 33653420
pmcid: 7923338
Lahmadi M, Beddar L, Rouibah AL, Boumegoura A, Boufendi H, Temim A et al. Analysis of EGFR mutation status in Algerian patients with non-small cell lung cancer. Asian Pac J Cancer Prev. 2021;1;22(4):1063–1068. https://doi.org/10.31557/APJCP.2021.22.4.1063
Jazieh AR, Bounedjar A, Bamefleh H, Alfayea T, Almaghraby HQ, Belarabi A, et al. Expression of immune response markers in Arab patients with lung cancer. JCO Glob Oncol. 2020;6:1218–24. https://doi.org/10.1200/GO.20.00107
doi: 10.1200/GO.20.00107
pubmed: 32749860